Avanir   Report issue

Contributed to NME For profit Phase 1 Phase 3 Phase 4
Founded: Aliso Vieja CA United States (1998)
Status: Acquired by Otsuka (2014)

Organization Overview

First Clinical Trial
2001
NCT00021697
First Marketed Drug
2000
docosanol (abreva)
First NDA Approval
2000
docosanol (abreva)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Avanir Pharmaceuticals | AVANIR PHARMS | Lidak

Indications

Approved Indications


 

Herpes Labialis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Alzheimer Disease (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 3)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Dementia (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Depressive Disorder, Treatment-Resistant (Phase 2)

Diabetic Neuropathies (Phase 3)

Disease (Phase 2)

Disease Progression (Phase 2)

Disruptive, Impulse Control, and Conduct Disorders (Phase 2)

Dyskinesias (Phase 2)

Headache (Phase 3)

Migraine Disorders (Phase 3)

Motor Neuron Disease (Phase 3)

Multiple Sclerosis (Phase 3)

Neuralgia (Phase 2)

Parkinson Disease (Phase 3)

Psychomotor Agitation (Phase 3)

Schizophrenia (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial APIs: 8